Huangkui Capsule Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Macrophage Activation by Suppressing Inflammation and Oxidative Stress in Mice
Overview
Authors
Affiliations
Background: Huangkui capsule (HKC) comprises the total flavonoid extract of flowers of (L.) Medicus. This study aimed to explore the effects of HKC on lipopolysaccharide- (LPS-) induced acute lung injury (ALI) in mice and LPS-stimulated RAW 264.7 cells.
Methods: Enzyme-linked immunosorbent assay, histopathology, spectrophotometry, and quantitative real-time polymerase chain reaction were used for the assessments. Statistical analysis was performed using a one-way analysis of variance.
Results: LPS significantly increased lung inflammation, neutrophil infiltration, and oxidative stress and downregulated lung miR-451 expression. Treatment with HKC dramatically, reduced the total cell count in the bronchoalveolar lavage fluid (BALF), and inhibited myeloperoxidase activity in the lung tissues 24 h after LPS challenge. Histopathological analysis demonstrated that HKC attenuated LPS-induced tissue oedema and neutrophil infiltration in the lung tissues. Additionally, the concentrations of tumour necrosis factor- (TNF-) and interleukin- (IL-) 6 in BALF and IL-6 in the plasma reduced after HKC administration. Moreover, HKC could enhance glutathione peroxidase and catalase activities and upregulate the expression of miR-451 in the lung tissues. In vitro experiments revealed that HKC inhibited the production of nitric oxide, TNF-, and IL-6 in LPS-induced RAW 264.7 cells and mouse primary peritoneal macrophages. Additionally, HKC downregulated LPS-induced transcription of TNF and IL-6 in RAW 264.7 cells.
Conclusions: These findings suggest that HKC has anti-inflammatory and antioxidative effects that may protect mice against LPS-induced ALI and macrophage activation.
Lou L, Xiang C, Hu Y, Yang J Eur J Med Res. 2025; 30(1):107.
PMID: 39962570 PMC: 11831811. DOI: 10.1186/s40001-024-02151-5.
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
Terkeltaub R Drugs. 2023; 83(16):1501-1521.
PMID: 37819612 DOI: 10.1007/s40265-023-01944-y.
Wang S, Chang C, Hsuan C, Chang T, Chen Y, Wang Y Bioengineering (Basel). 2022; 9(10).
PMID: 36290563 PMC: 9598102. DOI: 10.3390/bioengineering9100596.
Chen Y, Zhou Y, Wang Q, Chen J, Chen H, Xie H J Immunol Res. 2022; 2022:1800401.
PMID: 36213326 PMC: 9537000. DOI: 10.1155/2022/1800401.
Wu J, Cao M, Hu M, Gong Y, Xue J, Yang Y Evid Based Complement Alternat Med. 2022; 2022:9855411.
PMID: 36193125 PMC: 9526647. DOI: 10.1155/2022/9855411.